Prostate Cancer Treatment

749

When hormone-suppression therapy stops working for some men with advanced prostate cancer, they’re left with chemotherapy—which guarantees nausea and vomiting but offers little hope of a longer life. But interventional radiologist Dr. Henry Krebs III and Dr. Peter Rossi, medical director of radiation oncology at Saint Joseph’s Hospital, are the first in Georgia to offer the newly FDA-approved Xofigo (RA 223). The injectable radiation product eases bone pain and has increased survival rates by 30 percent.

This article originally appeared in our November 2013 issue.

Advertisement